The Central Hospital of Xinxiang

Xinxiang, China

The Central Hospital of Xinxiang

Xinxiang, China
SEARCH FILTERS
Time filter
Source Type

Yin Q.-S.,Zhengzhou University | Chen L.,Zhengzhou University | Mi R.-H.,Zhengzhou University | Ai H.,Zhengzhou University | And 3 more authors.
Medical Science Monitor | Year: 2016

Background: Currently available antithrombotic prophylaxis is not perfectly reliable in elderly patients. The aim of this retrospective study was to evaluate the efficacy and safety of Compound Danshen Tablet (CDT) in preventing thromboembolism in multiple myeloma (MM) patients treated with thalidomide-based regimens. Material/Methods: MM patients treated with thalidomide-based regimens were retrospectively reviewed between January 2008 and March 2015. Patients were categorized into 3 cohorts based on thromboembolic prophylaxis used: CDT, Warfarin Tablet, and no prophylaxis. Venous thromboembolism (VTE), other adverse effects (AEs), and the changes of D-dimer and fibrinogen levels were monitored. Results: Seven out of 313 MM patients (2.24%) developed venous thrombosis events (VTE) in this retrospective study, all clustering in the no prophylaxis cohort. Three patients of the Warfarin cohort (3.19%) experienced hemorrhage. Neither VTE events nor serious AEs were observed in the CDT cohort. Following Compound Danshen or Warfarin treatment for 3 months, the D-dimer and fibrinogen levels (in particular the D-dimer level) (all P<0.05), were obviously decreased relative to their respective baselines and the no prophylaxis cohort. In contrast, the 2 blotting parameters were significantly increased in the no prophylaxis cohort relative to the baseline level (All P<0.05), and were even higher in the patients experiencing VTE compared to the no VTE patients (P<0.0001 and P=0.016, respectively). Conclusions: Our findings indicate CDT is an effective therapy for preventing VTE in MM patients treated with thalidomidebased regimens, and is well tolerated in long-term use. © Med Sci Monit.


PubMed | The Central Hospital of Xinxiang, The Second Peoples Hospital of Jiaozuo and Zhengzhou University
Type: | Journal: Medical science monitor : international medical journal of experimental and clinical research | Year: 2016

BACKGROUND Currently available antithrombotic prophylaxis is not perfectly reliable in elderly patients. The aim of this retrospective study was to evaluate the efficacy and safety of Compound Danshen Tablet (CDT) in preventing thromboembolism in multiple myeloma (MM) patients treated with thalidomide-based regimens. MATERIAL AND METHODS MM patients treated with thalidomide-based regimens were retrospectively reviewed between January 2008 and March 2015. Patients were categorized into 3 cohorts based on thromboembolic prophylaxis used: CDT, Warfarin Tablet, and no prophylaxis. Venous thromboembolism (VTE), other adverse effects (AEs), and the changes of D-dimer and fibrinogen levels were monitored. RESULTS Seven out of 313 MM patients (2.24%) developed venous thrombosis events (VTE) in this retrospective study, all clustering in the no prophylaxis cohort. Three patients of the Warfarin cohort (3.19%) experienced hemorrhage. Neither VTE events nor serious AEs were observed in the CDT cohort. Following Compound Danshen or Warfarin treatment for 3 months, the D-dimer and fibrinogen levels (in particular the D-dimer level) (all P<0.05), were obviously decreased relative to their respective baselines and the no prophylaxis cohort. In contrast, the 2 blotting parameters were significantly increased in the no prophylaxis cohort relative to the baseline level (All P<0.05), and were even higher in the patients experiencing VTE compared to the no VTE patients (P<0.0001 and P=0.016, respectively). CONCLUSIONS Our findings indicate CDT is an effective therapy for preventing VTE in MM patients treated with thalidomide-based regimens, and is well tolerated in long-term use.


Zhou J.,Xiamen University | Wu S.-G.,Xiamen University | Wang J.-J.,The Central Hospital of Xinxiang | Sun J.-Y.,Sun Yat Sen University | And 4 more authors.
Cancer Research and Treatment | Year: 2015

Purpose: The purpose of this study was to assess the value of ovarian ablation using goserelin in premenopausal patients with stage II/III hormone receptor-positive breast cancer without chemotherapy-induced amenorrhea (CIA). Materials and Methods: We retrospectively reviewed the data of breast patients treated between October 1999 and November 2007 without CIA. The Kaplan-Meier method was used for calculation of the survival rate. Log rank method and Cox regression analysis were used for univariate and multivariate prognostic analysis. Results: The median follow-up period was 61 months. Initially, 353 patients remained without CIA after chemotherapy and 98 among those who received goserelin and tamoxifen (TAM). In univariate analysis, goserelin improved locoregional recurrence-free survival (LRFS) (98.9% vs. 94.1%, p=0.041), distant metastasis-free survival (DMFS) (85.4% vs. 71.9%, p=0.006), disease-free survival (DFS) (85.4% vs. 71.6%, p=0.005), and overall survival (OS) (93.5% vs. 83.5%, p=0.010). In multivariate analysis, goserelin treatment was an independent factor influencing DMFS (hazard ratio [HR], 1.603; 95% confidence interval [CI], 1.228 to 2.092; p=0.001), DFS (HR, 1.606; 95% CI, 1.231 to 2.096; p=0.001), and OS (HR, 3.311; 95% CI, 1.416 to 7.742; p=0.006). In addition, treatment with goserelin resulted in significantly improved LRFS (p=0.039), DMFS (p=0.043), DFS (p=0.036), and OS (p=0.010) in patients aged < 40 years. In patients aged ≥ 40 years, goserelin only improved DMFS (p=0.028) and DFS (p=0.027). Conclusion Ovarian ablation with goserelin plus TAM resulted in significantly improved therapeutic efficacy in premenopausal patients with stage II/III hormone receptor-positive breast cancer without CIA. © 2015 by the Korean Cancer Association.


PubMed | The Central Hospital of Xinxiang, Sun Yat Sen University and Xiamen University
Type: Journal Article | Journal: Cancer research and treatment : official journal of Korean Cancer Association | Year: 2015

The purpose of this study was to assess the value of ovarian ablation using goserelin in premenopausal patients with stage II/III hormone receptor-positive breast cancer without chemotherapy-induced amenorrhea (CIA).We retrospectively reviewed the data of breast patients treated between October 1999 and November 2007 without CIA. The Kaplan-Meier method was used for calculation of the survival rate. Log rank method and Cox regression analysis were used for univariate and multivariate prognostic analysis.The median follow-up period was 61 months. Initially, 353 patients remained without CIA after chemotherapy and 98 among those who received goserelin and tamoxifen (TAM). In univariate analysis, goserelin improved locoregional recurrence-free survival (LRFS) (98.9% vs. 94.1%, p=0.041), distant metastasis-free survival (DMFS) (85.4% vs. 71.9%, p=0.006), disease-free survival (DFS) (85.4% vs. 71.6%, p=0.005), and overall survival (OS) (93.5% vs. 83.5%, p=0.010). In multivariate analysis, goserelin treatment was an independent factor influencing DMFS (hazard ratio [HR], 1.603; 95% confidence interval [CI], 1.228 to 2.092; p=0.001), DFS (HR, 1.606; 95% CI, 1.231 to 2.096; p=0.001), and OS (HR, 3.311; 95% CI, 1.416 to 7.742; p=0.006). In addition, treatment with goserelin resulted in significantly improved LRFS (p=0.039), DMFS (p=0.043), DFS (p=0.036), and OS (p=0.010) in patients aged < 40 years. In patients aged 40 years, goserelin only improved DMFS (p=0.028) and DFS (p=0.027).Ovarian ablation with goserelin plus TAM resulted in significantly improved therapeutic efficacy in premenopausal patients with stage II/III hormone receptor-positive breast cancer without CIA.


Zhou X.-J.,Nanchang University | Wu F.-L.,The Central Hospital of Xinxiang | Jiang L.-L.,Nanchang University | Huang L.-F.,Nanchang University | Li G.-H.,Nanchang University
International Journal of Peptide Research and Therapeutics | Year: 2016

To investigate vasoactive intestinal peptide (VIP) effect on dendritic cells (DCs) to gastric cancer (GC) cells in vitro involving immune escape mechanism of GC, we observed DC-SIGN (CD209), Ii chain (CD74), MHC-II and collaborative costimulatory molecules CD40, CD80, CD86 expressions in DCs, which co-incubated with GC cells and VIP. Human umbilical cord blood (HUCB) were obtained from healthy volunteers and human mononuclear cells were isolated from HUCB by density gradient centrifugation. Monocytes were purified from mononuclear cells using adherence separation and were treated with recombinant human granulocyte–macrophage colony-stimulating factor (rh GM-CSF), recombinant human interleukin-4 (rh IL-4) to induce immature monocyte-derived DCs (moDCs). Recombinant human tumor necrosis factor (rh TNF-α) was added on the 5th day to induce mature moDCs. Mature moDCs were collected on the 10th day, and co-incubated with MKN45, VIP and mannan, respectively. CD1a and CD83 expressions were detected by immunocytochemistry. VIP, VPAC1, CD209, CD74, MHC-II, CD40, CD80 and CD86 expressions of DCs were detected by immunocytochemistry and RT-PCR. VPAC1 was detected in DCs, but VIP did not detected in DCs. When DCs were co-incubated with MKN45 cells, MKN45 cells could inhibit DCs’ expressions of CD209, CD74, MHC-II, CD40, CD80 and CD86 in the mRNA and protein levels (p < 0.05), and VIP could further inhibit CD209, CD74, MHC-II, CD40, CD80 and CD86 expressions of DCs in the mRNA and protein levels (p < 0.05). The inhibition could not been reversed by mannan. CD209 was positively correlated with CD74, MHC-II, CD40, CD80 and CD86 in mRNA level and protein expression intensity in DCs. VIP could inhibit CD209, CD74, MHC-II, CD40, CD80 and CD86 expressions of DCs, and inhibit antigen-presenting ability of DCs. VIP may promote immune escape of GC by inhibiting CD209, CD74, MHC-II, CD40, CD80 and CD86 expressions of DCs. © 2016 Springer Science+Business Media New York


Wei W.,The Central Hospital of Xinxiang | Li B.-Q.,The Central Hospital of Xinxiang | Li R.-X.,The Central Hospital of Xinxiang | Peng X.,The Central Hospital of Xinxiang
World Chinese Journal of Digestology | Year: 2015

AIM: To evaluate and compare the clinical outcomes of transabdominal and transperineal surgical procedures for patients with complete rectal prolapse. METHODS: A retrospective study was performed of patients with complete rectal prolapse who received surgical treatment at the Central Hospital of Xinxiang between March 1995 and May 2014. Patients were classified according to the type of operation: transabdominal procedure (n = 64) and transperineal procedure (n = 40). Clinical effects were compared for the two groups. RESULTS: There were more young patients and males in the transabdominal group than in the transperineal group. Compared with the transperineal group, the transabdominal group had longer operating time (165 min ± 67 min vs 70 min ± 38 min, P < 0.001), longer hospital stay (10 d ± 4 d vs 7 d ± 2 d, P < 0.001), but a lower overall recurrence rate (6.3% vs 15.0%, P < 0.05). The overall rate of complications was similar between the two groups (10.9% vs 6.8%, P > 0.05). The patients in the transabdominal group complained mor e f r equent ly of constipation than of incontinence, conversely, in the transperineal group of incontinence than of constipation. CONCLUSION: The two approaches for treating complete rectal prolapse did not differ with regard to postoperative morbidity, but recurrence occurs frequently among patients in the transperineal group. Surgeons should carefully assess the condition of patients before operation and select the appropriate surgical approach for treating complete rectal prolapse. © 2015 Baishideng Publishing Group Inc. All rights reserved.


Wei W.,the Central Hospital of Xinxiang | Li R.-X.,the Central Hospital of Xinxiang | Shang X.-J.,the Central Hospital of Xinxiang | Peng X.,the Central Hospital of Xinxiang
World Chinese Journal of Digestology | Year: 2015

AIM: To evaluate the efficacy of an improved surgical procedure for treatment of puborectalis syndrome. METHODS: This prospective randomized study included 54 patients suffering from puborectalis syndrome. They were randomized into two groups: a control group which included 27 patients who underwent partial division of puborectalis and an observation group which included 27 patients who received an improved surgical procedure (partial division of puborectalis plus rectal serosal gomphosis and lateral internal sphincterotomy). The total effective rate and recurrence rate were compared for the two groups. RESULTS: After one year and a half, the total effective rate in the observation group was 92.6%, significantly higher than that in the control group (59.3%, P < 0.05). The recurrence rate in theobservation group was 3.8%, significantly lower than that in control group (36%, P < 0.05). CONCLUSION: The improved surgery has low recurrence rate and high safety. © 2015 Baishideng Publishing Group Inc. All rights reserved.


Wei W.,The Central Hospital of Xinxiang | Li R.-X.,The Central Hospital of Xinxiang | Peng X.,The Central Hospital of Xinxiang | Lv J.-D.,The Central Hospital of Xinxiang
World Chinese Journal of Digestology | Year: 2015

Aim: To compare the results of transanal vs transvaginal repair of symptomatic rectocele and to determine the long-term clinical outcomes according to the change in the depth of the rectocele after the procedure. Methods: This study included 50 women suffering from rectocele. They were randomized into two groups: 25 women (group A) receiving a transanal repair and 25 (group B) receiving a transvaginal repair. The relevant postoperative indexes were compared for the two groups. Results: At 12 mo after surgery, 17 women in each group (group A/B, 77%/74%) reported improvement of their symptoms. However, only 11 and 13 women of groups A and B (group A/B, 55%/59%), respectively, maintained their improvement during the median follow-up of 50 mo. Better results were reported in patients with a greater change in the depth of their rectocele (≥4 cm) after the procedure (P = 0.001). Conclusion: In both procedures, clinical outcomes might become progressively worse as the length of the follow-up is increased. A preoperative larger rectocele might have a better postoperative outcome. © 2015 Baishideng Publishing Group Inc. All rights reserved.


Wei W.,The Central Hospital of Xinxiang | Shang X.-J.,The Central Hospital of Xinxiang | Lv B.-Z.,The Central Hospital of Xinxiang
World Chinese Journal of Digestology | Year: 2011

AIM: To identify differentially expressed serum proteins between preoperative patients with hereditary nonpolyposis colorectal cancer (HNPCC) and those with sporadic colorectal cancer to find potential markers for the diagnosis of HNPCC. METHODS: The composition of serum proteins was detected by surface-enhanced laser desorption/ ionization time-of-flight mass spectrometry (SELDI-TOF-MS) and protein chip assay in 20 preoperative HNPCC patients and 25 patients with sporadic colorectal cancer. Discriminatory serum protein profiles were analyzed with the Biomarker Wizard software and Biomarker Pattern software. RESULTS: Two proteins (m/z 7 516.68 Da and 4 827.07 Da) were chosen to create a decision classification tree model which could discriminate the two groups of patients. In the test mode, the accuracy, sensitivity, specificity, and positive predictive value of the model for prediction of HNPCC was 86.7%, 72.3%, 95.1% and 92.5%, respectively, while the corresponding values for blinded validation were 75.6%, 100%, 69.8% and 99.2%, respectively. CONCLUSION: The classification tree model constructed with two differentially expressed proteins identified by SELDI-TOF-MS between HNPCC patients and patients with sporadic colorectal cancer possesses high sensitivity and specificity in the prediction of HNPCC.


PubMed | the Central Hospital of Xinxiang
Type: Journal Article | Journal: Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology | Year: 2016

MicroRNAs (miRNAs) are dysregulated in a wide range of malignant diseases, confirming their crucial role in tumor metastasis. MiRNA-30a-5p, a member of the miR-30 family, has been implicated in many types of cancers, including colorectal cancer, a leading cause of death worldwide.qRT-PCR, Western blot, Transwell assay,luciferase reporter assay were performed in the present study.In this study, miR-30a-5p was found to be significantly downregulated in human colorectal cancer tissue specimens and cell lines compared with non-cancerous tissues and cells. The overexpression of miR-30a-5p inhibited the migratory and invasive abilities of colorectal cancer cells and suppressed the epithelial-mesenchymal transition, a crucial process in metastasis. Bioinformatic algorithms and luciferase reporter assays revealed that integrin 3 (ITGB3) is a direct target of miR-30a-5p. Importantly, overexpression of ITGB3 in colorectal cancer cells rescued these cells from miR-30a-5p-mediated suppression of metastasis and restored the epithelial-mesenchymal transition.Taken together, our study provides the first evidence that miR-30a-5p suppresses colon cancer metastasis through the inhibition of ITGB3. Thus, targeting miR-30a-5p might serve as a promising therapeutic strategy for the treatment of colorectal cancer.

Loading The Central Hospital of Xinxiang collaborators
Loading The Central Hospital of Xinxiang collaborators